Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2749-2751

  Debets Ossenkopp, Y J ^a   Brinkman, A B ^a   Kuipers, E J ^a   Vandenbroucke Grauls, C M J E ^a   Kusters, J G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; RIBOSOME RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; GENE MUTATION; GROWTH RATE; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPERON; POINT MUTATION; PRIORITY JOURNAL;

EID: 0031683997     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2749     Document Type: Article

References (14)

1. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 1989. Current protocols in molecular biology. Greene Publishing Associates and Wiley Interscience, New York, N.Y.
2. Debets-Ossenkopp, Y. J., M. Sparrius, J. G. Kusters, J. J. Kolkman, and C. M. J. E. Vandenbroucke-Grauls. 1996. Mechanism of clarithromycin resistance in clinical isolates of H. pylori. FEMS Microbiol. Lett. 142:37-42.
3. The European Helicobacter Pylori Study Group. 1997. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 41:8-13.
4. Hultén, K., A. Gibreel, O. Sköld, and L. Engstrand. 1997. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob. Agents Chemother. 41:2550-2553.
5. Marshall, B. J., J. R. Warren, E. D. Blincow, M. Philips, C. S. Goodwill, R. Murray, S. J. Blackbourn, T. E. Waters, and C. R. Sanderson. 1988. Prospective double-blind trial of duodenal relapse after eradication of Campylobacter pylori. Lancet ii:1437-1441.
6. Nash, K. A., and C. B. Inderlied. 1995. Genetic basis ot macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob. Agents Chemother. 39:2625-2630.
7. NIH Consensus Conference. 1994. H. pylori in peptic ulcer disease. JAMA 272:65-69.
8. Shimada, A. 1996. PCR-based site-directed mutagenesis. Methods Mol. Biol. 57:157-165.
9. Stone, G. G., D. Shortridge, J. Versalovic, J. Beyer, R. K. Flamm, D. Y. Graham, A. T. Ghoneim, and S. K. Tanaka. 1997. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob. Agents Chemother. 41:712-714.
10. Taylor, D. E., Z. Ge, D. Purych, T. Lo, and K. Hiratsuka. 1997. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother. 41:2621-2628.
11. Versalovic, J., D. Shortridge, K. Kibler, M. V. Griffy, J. Beyer, R. K. Flamm, S. K. Tanaka, D. Y. Graham, and M. F. Go. 1996. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 40:477-480.
12. Walsh, J. H., and W. L. Peterson. 1995. The treatment ot Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 333: 984-991.
13. Wang, Y., K. P. Roos, and D. E. Taylor. 1993. Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker. J. Gen. Microbiol. 139:2485-2493.
14. Xia, H. X., M. Buckley, C. T. Keane, and C. A. O'Morain. 1996. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J. Antimicrob. Chemother. 37:473-481.